尼莫地平治疗老年痴呆症

Nimodipine in the treatment of old age dementias.

作者信息

Ban T A, Morey L, Aguglia E, Azzarelli O, Balsano F, Marigliano V, Caglieris N, Sterlicchio M, Capurso A, Tomasi N A

机构信息

Department of Psychiatry, Vanderbilt University, Nashville, TN.

出版信息

Prog Neuropsychopharmacol Biol Psychiatry. 1990;14(4):525-51. doi: 10.1016/0278-5846(90)90005-2.

DOI:10.1016/0278-5846(90)90005-2

Abstract

In a multicenter, placebo-controlled, double-blind clinical study in 178 elderly patients with cognitive decline, nimodipine, a calcium antagonist was found to be a therapeutically effective agent in the treatment of old age dementias. 2. Treatment with 90 mg of nimodipine administered orally in divided doses for 12 weeks was significantly superior to an inactive placebo on all outcome measures including the Wechsler Memory Scale, the Mini Mental State Examination, the Global Deterioration Scale, the Sandoz Clinical Assessment Geriatric Scale, the Plutchik Geriatric Rating Scale, the Severity of Illness and Global Improvement Scales of Clinical Global Impression, and the Hamilton Psychiatric Rating Scale for Depression. 3. Adverse effects with nimodipine were few and mild. The drug was equally well tolerated and equally effective in the two major dementias of old age, i.e., primary degenerative and multi-infarct. The number of abnormal laboratory test readings remained essentially unchanged from pre-treatment to post-treatment.

摘要

在一项针对178名认知功能衰退老年患者的多中心、安慰剂对照、双盲临床研究中，发现钙拮抗剂尼莫地平是治疗老年痴呆症的有效药物。2. 12周内分剂量口服90毫克尼莫地平进行治疗，在所有评估指标上均显著优于无活性的安慰剂，这些指标包括韦氏记忆量表、简易精神状态检查表、总体衰退量表、桑多兹老年临床评估量表、普拉奇克老年评定量表、临床总体印象的疾病严重程度和总体改善量表，以及汉密尔顿抑郁量表。3. 尼莫地平的不良反应少且轻微。在老年的两种主要痴呆症，即原发性退行性痴呆和多发梗死性痴呆中，该药物的耐受性相同且疗效相同。从治疗前到治疗后，实验室检查异常读数的数量基本保持不变。